Innovair Nexthaler (Formoterol Fumarate Dihydrate, Beclometasone Dipropionate Anhydrous)

Formoterol fumarate is a long‑acting β2‑adrenergic agonist that binds to β2 receptors on airway smooth muscle cells. This binding activates adenylate cyclase, increasing cyclic AMP levels, which leads to relaxation of the smooth muscle and sustained bronchodilation, helping keep the airways open for several hours after inhalation.

The dose of Innovair Nexthaler is determined by the prescribing clinician based on the individual’s disease severity, response to therapy, and clinical guidelines. The prescriber will specify the number of inhalations to be taken each day, typically one or two inhalations, and may adjust the regimen during follow‑up visits.

Safety data for Innovair Nexthaler in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss the risks and benefits with the patient and consider alternative therapies when appropriate.

To order Innovair Nexthaler, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.

Innovair Nexthaler combines formoterol, a long‑acting β2‑agonist, with beclometasone, an inhaled corticosteroid, similar to other LABA/ICS products such as Symbicort or Budesonide/Formoterol. Its dry‑powder inhaler format may offer a breath‑actuated delivery that does not require propellants, which some patients prefer. Clinical efficacy and safety are comparable when used according to guideline‑based dosing.

Innovair Nexthaler should be stored at ambient temperature, below 25 °C, in a dry environment. Keep the device in its original packaging to protect it from moisture and humidity. Do not expose the inhaler to extreme heat or direct sunlight, and keep it out of reach of children.

To use Innovair Nexthaler, the patient should first open the mouthpiece, exhale fully away from the device, then place the inhaler between the lips and inhale sharply and deeply through the mouth. Hold the breath for a few seconds, then exhale slowly. Rinse the mouth with water after each use to reduce the risk of oral candidiasis.

Serious risks include paradoxical bronchospasm, which can worsen breathing and requires immediate medical attention, and severe allergic reactions such as anaphylaxis. Cardiovascular events like significant tachycardia, arrhythmias, and hypokalemia may also occur, especially at higher doses or in susceptible individuals. Regular monitoring and prompt reporting of symptoms are essential.

Innovair Nexthaler is contraindicated in patients with a known hypersensitivity to formoterol, beclometasone, or any excipients in the inhaler. It should not be used for the relief of acute bronchospasm. Caution is advised in individuals with severe cardiovascular disorders, uncontrolled hypertension, or a history of paradoxical bronchospasm.